Characterization of a new cancer-associated mutant of p53 with a missense mutation (K351N) in the tetramerization domain

Cell Cycle

Volumn 8, Issue 20, 2009, Pages 3396-3405

  Muscolini, Michela ^a   Montagni, Elisa ^a   Caristi, Silvana ^a   Nomura, Takao ^b   Kamada, Rui ^b   Di Agostino, Silvia ^c   Corazzari, Marco ^d   Piacentini, Mauro ^d,e   Blandino, Giovanni ^c   Costanzo, Antonio ^e,f   Sakaguchi, Kazuyasu ^b   Tuosto, Loretta ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b HOKKAIDO UNIVERSITY   (Japan)

^c Translational Oncogenomic Unit   (Italy)

^d NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f Rome Oncogenomic Center   (Italy)

Author keywords

Apoptosis; Chemotherapy resistance; p53; Tumor suppressor

Indexed keywords

ASPARAGINE; CISPLATIN; LYSINE; MUTANT PROTEIN; PROTEIN BAX; PROTEIN P53; TETRAMER;

AMINO ACID SUBSTITUTION; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MISSENSE MUTATION; NUCLEAR EXPORT SIGNAL; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STABILITY; TRANSACTIVATION;

EID: 70350223957     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.20.9910     Document Type: Article

References (45)

1. Lavarino C, Delia D, Di Palma S, Zunino F, Pilotti S. p53 in drug resistance in ovarian cancer. Lancet 1997; 349:1556. (Pubitemid 27216387)
2. Weisz L, Oren M, Rotter V. Transcription regulation by mutant p53. Oncogene 2007; 26:2202-2211
3. Teicher BA. Hipoxia and drug resistance. Cancer Metastasis Rev 1994; 13:139-168
4. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-310
5. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26:1324-1337 (Pubitemid 46328466)
6. Miyashita T, Krajewski S, krajewska M, Wang HG, Lin HK, Lieberman DA, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9:1799-1805
7. Palacious G, Crawford HC, Vaseva A, Moll UM. Mitochondrially targeted wild-type p53 induces apoptosis in a solid human tumor xenograft model. Cell Cycle 2008; 7:2584-2590
8. Wolff S, Erster S, Palacios G, Moll UM. p53's mitochondrial translocation and MOMP action is independent of Puma and Bax and severely disrupt mitochondrial membrane integrity. Cell Res 2008; 18:733-744 (Pubitemid 351948223)
9. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, Green DR. Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis. Science 2004; 303:1010-1014 (Pubitemid 38209704)
10. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, Moll UM. p53 Has a Direct Apoptogenic Role at the Mitochondria. Molecular Cell 2003; 11:577-590 (Pubitemid 36385115)
11. Soussi T. A critical analysis of p53 gene alterations. In: Wiman K, Hainaut P, eds. 25 Years of p53. Berlin: Springer 2005; 225-292
12. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and reccomendations to users. Hum Mutat 2002; 19:607-614 (Pubitemid 34556481)
13. Chène P. The role of tetramerization in p53 function. Oncogene 2001; 20:2611-2617
14. Muscolini M, Cianfrocca R, Sajeva A, Mozzetti S, Ferrandina G, Costanzo A, Tuosto L. Trichostatin A upregulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells. Mol Cancer Ther 2008; 7:1410-1419
15. Liu JR, Opipari AW, Tan L, Jiang Y, Zhang Y, Tang H, Nuñez G. Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance. Cancer Res 2002; 62:924-931 (Pubitemid 34126974)
16. Perego P, Gatti L, Righetti SC, Beretta GL, Carenini N, Corna E, et al. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells. Int J Cancer 2003; 105:617-624 (Pubitemid 36687728)
17. Yang X, Zheng F, Xing H, Gao Q, Wei W, Lu Y, et al. Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of anti-apoptotic proteins in ovarian cancer. J Cancer res Clin Oncol 2004; 130:423-428 (Pubitemid 39044346)
18. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, et al. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 1987; 47:414-418 (Pubitemid 17009602)
19. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80:293-299
20. Gasco M, Crook T. p53 family members and chemoresistance in cancer: what we know and what we need to know. Drug Resist Updates 2003; 6:323-328 (Pubitemid 38173583)
21. Mateu MG, Fersht AR. Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligomerization status of tumor suppressor p53 tetramerization domain. EMBO J 1998; 17:2748-2758 (Pubitemid 28227121)
22. Sakamoto H, Lewis MS, Kodama H, Appella E, Sakaguchi K. Specific sequences from the carboxyl terminus of human p53 gene product form anti-parallel tetramers in solution. Proc Natl Acad Sci USA 1994; 91:8974-8978
23. Imagawa T, Terai T, Yamada Y, Kamada R, Sakaguchi K. Evaluation of transcriptional activity of p53 in individual living mammalian cells. Anal Biochem 2009; 387:249-256
24. Halazonetis TD, Kandil AN. Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J 1993; 12:5057-5064 (Pubitemid 23358494)
25. Lakin ND, Jackson SP. Regulation of p53 in response to DNA damage. Oncogene 1999; 18:7644-7655
26. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, et al. p53AIP1, a Potential Mediator of p53-Dependent Apoptosis, and Its Regulation by Ser-46-Phosphorylated p53. Cell 2000; 102:849-862
27. Kartasheva NN, Contente A, Lenz-Stopller C, Roth J, Dobbelstein M. p53 induces the expression of its antagonist p73ΔN, establishing an autoregulatory feedback loop. Oncogene 2002; 21:4715-4727 (Pubitemid 34879447)
28. Vossio S, Palescandolo E, Pediconi N, Moretti F, Balsano C, Levrero M, Costanzo A. DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest. Oncogene 2002; 21:3796-3803 (Pubitemid 34620543)
29. Stommel JM, Marchenko ND, Jimenez GS, Moll UM, Hope TJ, Wahl GM. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellar localization and p53 activity by NES masking. EMBO J 1999; 18:1660-1872
30. Tasdemir E, Maiuri MC, Galluzzi L, Vitale I, Djavaheri-Mergny M, D'Amelio M, et al. Regulation of autophagy by cytoplasmic p53. Nat Cell Biol 2008; 10:676-686
31. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000; 77:81-137. (Pubitemid 29439303)
32. Rollenhagen C, Chene P. Characterization of p53 mutants identified in human tumors with a missense mutation in the tetramerization domain. Int J Cancer 1998; 78:372-376 (Pubitemid 28445377)
33. Balagurumoorthy P, Sakamoto H, Lewis MS, Zambrano N, Clore GM, Gronenborn AM, et al. Four p53 DNA-binding domain peptides bind natural p53-response elements and bend the DNA. Proc Natl Acad Sci USA 1995; 92:8591-8595
34. Clore GM, Omichinski JG, Sakaguchi K, Zambrano N, Sakamoto H, Appella E, Gronenborn AM. High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science 1995; 265:386-391 (Pubitemid 24259970)
35. Jeffrey PD, Gorina S, Pavletich NP. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstrom. Science 1995; 267:1498-1502
36. Lwin TZ, Durant JJ, Bashford D. A fluid salt-bridging cluster and the stabilization of p53. J Mol Biol 2007; 373:1334-1347 (Pubitemid 47539478)
37. Speidel D, Helmbold H, Deppert W. Dissection of transcriptional and non-transcriptional p53 activities in the response to genotoxic stress. Oncogene 2006; 25:940-953 (Pubitemid 43237712)
38. Kawaguchi Y, Ito A, Appella E, Yao T-P. Charge Modification at Multiple C-terminal Lysine Residues Regulates p53 Oligomerization and Its Nucleus-Cytoplasm Trafficking. Journal of Biological Chemistry 2006; 281:1394-1400 (Pubitemid 43752454)
39. Kruse JP, Gu W. MSL2 Promotes Mdm2-independent Cytoplasmic Localization of p53. J Biol Chem 2009; 284:3250-3263
40. Olivier M, Petitjean A, Marcel V, Pétré A, Mounawar M, Plymoth A, et al. Recent advances in p53 research: an interdisciplinary perspective. Cancer Gene Ther 2008; 16:1-12.
41. Chipuk JE, Maurer U, Green DR, Schuler M. Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell 2003; 4:371-381 (Pubitemid 37491098)
42. De Laurenzi V, Costanzo A, Barcaroli D, Terrinoni A, Falco M, Annicchiarico-Petruzzelli M, et al. Two new p73 splice variants, gamma and delta, with different transcriptional activity. J Exp Med 1998; 188:1763-1768 (Pubitemid 28516121)
43. Cianfrocca R, Muscolini M, Marzano V, Annibaldi A, Marinari B, Levrero M, et al. RelA/NFkappaB recruitment on the bax gene promoter antagonizes p73-dependent apoptosis in costimulated T cells. Cell Death Differ 2008; 15:354-363
44. Johnson CR, Morin PE, Arrowsmith CH, Freire E. Thermodynamic analysis of the structural stability of the tetrameric oligomerization domain of p53 tumor suppressor. Biochemistry 1995; 34:5309-5316
45. L gene promoters. Proceedings of the National Academy of Sciences of the United States of America 2004; 101:6098-6103